Thomas C. Gasser

Thomas C. Gasser's AcademicInfluence.com Rankings

Thomas C. Gasser

Medical

#1721

World Rank

#2091

Historical Rank

Neurology

#152

World Rank

#219

Historical Rank

medical Degrees

Thomas C. Gasser

Philosophy

#5199

World Rank

#7939

Historical Rank

Logic

#2517

World Rank

#3521

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Thomas C. Gasser's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Thomas C. Gasser Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas C. Gasser's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

MDS clinical diagnostic criteria for Parkinson's disease (2015) (3560)
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology (2004) (2782)
Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease (2009) (1770)
The ubiquitin pathway in Parkinson's disease (1998) (1615)
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease (2014) (1591)
Analysis of shared heritability in common disorders of the brain (2016) (1385)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study (2008) (1293)
Association between early-onset Parkinson's disease and mutations in the parkin gene. (2000) (1192)
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. (2009) (965)
MDS research criteria for prodromal Parkinson's disease (2015) (897)
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies (2011) (873)
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies (2019) (871)
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria (2009) (711)
The phenotypic spectrum of CADASIL: Clinical findings in 102 cases (1998) (689)
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. (2005) (576)
Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database (2012) (546)
A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. (1999) (528)
Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin (2007) (523)
A susceptibility locus for Parkinson's disease maps to chromosome 2p13 (1998) (492)
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. (2013) (451)
iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis (2014) (417)
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication (2007) (401)
Mutations in the gene encoding ɛ-sarcoglycan cause myoclonus–dystonia syndrome (2001) (397)
Priorities in Parkinson's disease research (2011) (391)
Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease (2014) (384)
Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. (2000) (381)
The natural history of multiple system atrophy: a prospective European cohort study (2013) (376)
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. (2013) (357)
EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease (2013) (355)
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. (2009) (335)
GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. (2008) (324)
DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. (2009) (322)
EFNS guidelines on diagnosis and treatment of primary dystonias (2011) (320)
Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling (2013) (313)
Update of the MDS research criteria for prodromal Parkinson's disease (2019) (313)
A prevalence study of primary dystonia in eight European countries (2000) (302)
Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress (2011) (297)
How much phenotypic variation can be attributed to parkin genotype? (2003) (296)
Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. (2016) (292)
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease (2017) (278)
Molecular pathogenesis of Parkinson disease: insights from genetic studies (2009) (274)
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. (2005) (271)
A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS‐ES Task Force (2006) (270)
SNCA variants are associated with increased risk for multiple system atrophy (2009) (263)
Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain (2008) (261)
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology (2004) (258)
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. (2005) (257)
Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. (2001) (253)
Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families (2002) (245)
Genomic investigation of α‐synuclein multiplication and parkinsonism (2008) (231)
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. (2011) (224)
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study (2008) (223)
GBA-associated PD presents with nonmotor characteristics (2011) (220)
Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration (2007) (213)
Complex relationship between Parkin mutations and Parkinson disease. (2002) (212)
Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry (2010) (212)
The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. (2004) (207)
Red flags for multiple system atrophy (2008) (198)
Multiple regions of α‐synuclein are associated with Parkinson's disease (2005) (195)
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease. (2018) (193)
Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. (2001) (192)
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial (2006) (191)
GBA‐associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study (2015) (190)
Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms (2019) (189)
Association of an interleukin 1α polymorphism with Alzheimer’s disease (2000) (185)
Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases (2017) (185)
Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis (2011) (184)
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. (2009) (183)
Novel mutation in the TOR1A (DYT1) gene in atypical, early onset dystonia and polymorphisms in dystonia and early onset parkinsonism (2001) (178)
Mendelian forms of Parkinson's disease. (2009) (173)
UCHL1 is a Parkinson's disease susceptibility gene (2004) (173)
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study (2015) (172)
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease (2006) (170)
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. (2013) (169)
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics (2009) (166)
Update on the genetics of Parkinson's disease (2007) (165)
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options (2009) (165)
Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis (2011) (164)
Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study (2013) (163)
Milestones in PD genetics (2011) (163)
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers (2014) (160)
Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. (2011) (159)
Variability of familial hemiplegic migraine with novel A1A2 Na+/K+-ATPase variants (2004) (156)
Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) (2010) (155)
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study (2002) (154)
The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted (2003) (152)
Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. (2009) (149)
The role of inflammation in sporadic and familial Parkinson’s disease (2013) (147)
123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism (1992) (146)
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities (2013) (144)
Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3v EGF-like repeat domains (2000) (140)
Reduced Cerebrovascular CO2 Reactivity in CADASIL: A Transcranial Doppler Sonography Study (2001) (137)
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease (2008) (137)
Clinical symptoms and possible anticipation in a large kindred of familial restless legs syndrome (1996) (137)
Analysis of differential DNA damage in the mitochondrial genome employing a semi-long run real-time PCR approach (2009) (136)
Large-scale replication and heterogeneity in Parkinson disease genetic loci (2012) (133)
Park6‐linked parkinsonism occurs in several european families (2002) (132)
Myoclonus–dystonia syndrome: ε‐sarcoglycan mutations and phenotype (2002) (132)
l -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism (2003) (131)
Phenotypic expression of the DYT1 mutation: A family with writer's cramp of juvenile onset (1998) (131)
Creatine supplementation lowers brain glutamate levels in Huntington’s disease (2005) (130)
[11C]PIB binding in Parkinson's disease dementia (2008) (128)
The prevalence of primary dystonia in the general community (2002) (125)
Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus (2015) (124)
The DYT1 gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. (1994) (124)
A genome-wide association study in multiple system atrophy (2016) (122)
Quantitative EEG analysis in early onset Alzheimer's disease: a controlled study. (1993) (122)
Radicular and nonradicular back pain in Parkinson's disease: A controlled study (2007) (121)
Computational analysis of open loop handwriting movements in Parkinson's disease: A rapid method to detect dopamimetic effects (1996) (120)
Time course of distant effects of local injections of botulinum toxin (1993) (120)
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease (2013) (119)
Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils (2017) (118)
Osteopontin is elevated in Parkinson’s disease and its absence leads to reduced neurodegeneration in the MPTP model (2007) (118)
Polygenic risk of Parkinson disease is correlated with disease age at onset (2015) (116)
The transcription factor PITX3 is associated with sporadic Parkinson's disease (2009) (115)
Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. (2001) (115)
Genetic basis of Parkinson’s disease: inheritance, penetrance, and expression (2011) (114)
Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect (2011) (114)
A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. (2013) (112)
Sequencing of the α-Synuclein Gene in a Large Series of Cases of Familial Parkinson's Disease Fails to Reveal any Further Mutations (1998) (110)
Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. (2013) (106)
CADASIL: skin biopsy allows diagnosis in early stages (1997) (106)
The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II (2007) (106)
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants (2012) (105)
Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways. (2017) (104)
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases (2015) (104)
Muscle and skin biopsies are a sensitive diagnostic tool in the diagnosis of CADASIL (1999) (104)
Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor (2012) (103)
The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. (2005) (101)
Inherited myoclonus-dystonia syndrome. (1998) (100)
A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia. (2015) (99)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture (2021) (99)
Movement disorder society criteria for clinically established early Parkinson's disease (2018) (96)
Prevention of interferon-stimulated gene expression using microRNA-designed hairpins (2009) (96)
Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. (2010) (96)
Genes associated with Parkinson syndrome (2008) (95)
Integrated molecular landscape of Parkinson’s disease (2017) (94)
Expanding Parkinson’s disease genetics: novel risk loci, genomic context, causal insights and heritable risk (2018) (94)
Expanding Parkinson’s disease genetics: novel risk loci, genomic context, causal insights and heritable risk (2018) (94)
Homo‐ and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment (2009) (94)
Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. (2019) (92)
NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases (2017) (92)
Quantitative EEG analysis in early onset Alzheimer's disease: correlations with severity, clinical characteristics, visual EEG and CCT. (1994) (88)
Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). (2011) (88)
Genetics of Parkinson's disease (1998) (88)
Parkinson patient fibroblasts show increased alpha-synuclein expression (2008) (88)
Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions (2020) (86)
Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (85)
Psychosocial aspects of Parkinson's disease (1993) (84)
Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes (1994) (84)
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. (2000) (83)
Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. (2000) (82)
Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the −2578AA genotype (2008) (82)
Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk (2018) (81)
Genetics of Parkinson's disease. (2005) (81)
Quantitative MRI in CADASIL (1999) (81)
The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. (2005) (80)
Sex-related influences on the frequency and age of onset of primary dystonia (1999) (79)
A placebo-controlled crossover trial of creatine in mitochondrial diseases (2000) (79)
Alpha‐synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients (2005) (79)
The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease (1999) (79)
The European Multiple System Atrophy-Study Group (EMSA-SG) (2005) (78)
The α‐synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases (1998) (78)
Service-Based Survey of Dystonia in Munich (2002) (78)
Genetic complexity and Parkinson's disease. (1997) (77)
A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa (2005) (77)
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2019) (77)
Three cases of CLIPPERS: a serial clinical, laboratory and MRI follow-up study (2011) (76)
Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism (2020) (76)
Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. (1992) (75)
The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I (2007) (75)
Myoclonus‐dystonia due to genomic deletions in the epsilon‐sarcoglycan gene (2005) (75)
German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations. (1997) (75)
Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease (2015) (75)
The new definition and diagnostic criteria of Parkinson's disease (2016) (74)
A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease (2011) (74)
Metformin reverses TRAP1 mutation‐associated alterations in mitochondrial function in Parkinson's disease (2017) (72)
123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism (1998) (72)
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data (2016) (71)
EFNS guidelines on the molecular diagnosis of mitochondrial disorders (2009) (70)
Ultrasound‐guided injection of the iliopsoas muscle with botulinum toxin in camptocormia (2008) (69)
Clinical and brain imaging characteristics in leucine‐rich repeat kinase 2–associated PD and asymptomatic mutation carriers (2011) (69)
NOTCH3 mutation involving three cysteine residues in a family with typical CADASIL (2001) (68)
ATP13A2 variants in early‐onset Parkinson's disease patients and controls (2009) (68)
Genetic comorbidities in Parkinson's disease. (2014) (67)
Predictive value of transcranial sonography in the diagnosis of Parkinson's disease (2006) (65)
Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease (2007) (64)
Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis (2009) (64)
α2 Macroglobulin and the risk of Alzheimer’s disease (2000) (63)
Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. (2013) (63)
Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease (2013) (63)
Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration (2013) (61)
Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease (2010) (61)
SUSCEPTIBILITY TO DYT1 DYSTONIA IN EUROPEAN PATIENTS IS MODIFIED BY THE D216H POLYMORPHISM (2008) (61)
Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. (2007) (60)
Genetics of Parkinson's disease (2001) (60)
Dystonia‐plus syndromes (2010) (60)
Single‐cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene (2009) (60)
Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia (2006) (59)
Genomic and proteomic biomarkers for Parkinson disease (2009) (59)
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin (2016) (58)
Correlations Between Clinical Findings and Magnetization Transfer Imaging Metrics of Tissue Damage in Individuals With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (2001) (58)
A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. (2007) (58)
Common variants of LRRK2 are not associated with sporadic Parkinson's disease (2005) (57)
EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias (2009) (56)
Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes (2001) (55)
Genetic assessment of familial and early‐onset Parkinson's disease in a Greek population (2014) (55)
Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. (2011) (54)
Sonographic abnormalities of brainstem structures in restless legs syndrome. (2008) (54)
A large genome scan for rare CNVs in amyotrophic lateral sclerosis. (2010) (53)
ATAXIA WITH OPHTHALMOPLEGIA OR SENSORY NEUROPATHY IS FREQUENTLY CAUSED BY POLG MUTATIONS (2009) (53)
Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus (2013) (53)
Inherited myoclonus‐dystonia syndrome: Narrowing the 7q21‐q31 locus in German families (2001) (52)
Inflammatory profile in LRRK2-associated prodromal and clinical PD (2016) (52)
NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. (2012) (52)
A rare truncating mutation in ADH1C (G78Stop) shows significant association with Parkinson disease in a large international sample. (2005) (52)
NOVEL ATP1A3 MUTATION IN A SPORADIC RDP PATIENT WITH MINIMAL BENEFIT FROM DEEP BRAIN STIMULATION (2008) (52)
Clinical differentiation of genetically proven benign hereditary chorea and myoclonus‐dystonia (2007) (51)
EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias (2010) (51)
Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly (2010) (50)
Sporadic rapid‐onset dystonia–parkinsonism syndrome: Failure of bilateral pallidal stimulation (2005) (50)
Genome‐wide association study in musician's dystonia: A risk variant at the arylsulfatase G locus? (2014) (50)
Candidate gene studies in focal dystonia (2003) (50)
Parkin interacts with the proteasome subunit α4 (2005) (50)
Additional rare variant analysis in Parkinson’s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance (2016) (50)
The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations (2005) (49)
Delta‐like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons (2008) (49)
Age and cause of death in mitochondrial diseases (1999) (49)
Use of support vector machines for disease risk prediction in genome‐wide association studies: Concerns and opportunities (2012) (48)
EFNS guidelines for the molecular diagnosis of neurogenetic disorders: motoneuron, peripheral nerve and muscle disorders (2011) (48)
Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). (1998) (47)
Parkinson’s disease: From human genetics to clinical trials (2015) (47)
Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia (2019) (47)
Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases (2011) (46)
GAG deletion in the DYT1 gene in early limb‐onset idiopathic torsion dystonia in Germany (1999) (46)
Abolishing the 1‐year rule: How much evidence will be enough? (2016) (45)
Cross-sectional study discloses a positive family history for Parkinson’s disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity (2007) (45)
RLS3: Fine-mapping of an autosomal dominant locus in a family with intrafamilial heterogeneity (2006) (44)
Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease (2007) (43)
The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism (2013) (43)
Psychiatric disorders, myoclonus dystonia and SGCE: an international study (2015) (43)
PARK6 is a common cause of familial parkinsonism (2002) (43)
Deep-brain-stimulation does not impair deglutition in Parkinson's disease. (2012) (43)
State of the art review: Molecular diagnosis of inherited movement disorders. Movement Disorders Society task force on molecular diagnosis (2003) (43)
Intrafamilial variability in fragile X–associated tremor/ataxia syndrome (2006) (43)
The Luxembourg Parkinson’s Study: A Comprehensive Approach for Stratification and Early Diagnosis (2018) (43)
SNCA: Major genetic modifier of age at onset of Parkinson's disease (2013) (42)
Parkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK) (2011) (41)
The D2 receptor Nco I allele: Absence of allelic association with migraine with aura (1998) (41)
“Jerky” dystonia in children: Spectrum of phenotypes and genetic testing (2009) (41)
Trial of Prasinezumab in Early-Stage Parkinson's Disease. (2022) (41)
Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis (2010) (40)
Correction: Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling (2013) (40)
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease (2021) (40)
Inflammatory profile discriminates clinical subtypes in LRRK2‐associated Parkinson's disease (2017) (40)
Genome-wide scan linkage analysis for Parkinson’s disease: the European genetic study of Parkinson’s disease (2004) (39)
[123]IBZM Binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy (1997) (39)
Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells (2020) (39)
Spinocerebellar ataxia type 6: Evidence for a strong founder effect among German families (1999) (38)
Inherited myoclonus-dystonia. (2004) (38)
Erratum: UCHL1 is a Parkinson's disease susceptibility gene (Annals of Neurology (April 2004) 55 (512-521)) (2004) (38)
Combined Flow Cytometric Analysis of Surface and Intracellular Antigens Reveals Surface Molecule Markers of Human Neuropoiesis (2013) (37)
Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson′s disease (2003) (37)
PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. (2009) (37)
The differential diagnosis and treatment of tremor. (2014) (36)
Effective thalamic deep brain stimulation for neuropathic tremor in a patient with severe demyelinating neuropathy (2009) (36)
Rare Variants in Neurodegeneration Associated Genes Revealed by Targeted Panel Sequencing in a German ALS Cohort (2016) (36)
Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants (2016) (36)
The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. (1996) (36)
Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease (2005) (36)
Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation (2008) (35)
Overview of the genetics of parkinsonism. (2003) (35)
Parkin interacts with the proteasome subunit alpha4. (2005) (35)
Toxic effects of lipid-mediated gene transfer in ventral mesencephalic explant cultures. (2006) (35)
No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort (2011) (35)
The parkin gene and its phenotype (2001) (34)
Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. (2009) (34)
Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls (2014) (34)
The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. (2010) (34)
The gene coding for glial cell line derived neurotrophic factor (GDNF) maps to chromosome 5p12-p13.1. (1995) (33)
The DYT1 GAG deletion is infrequent in sporadic and familial writer's cramp (2000) (33)
A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease (2021) (33)
Possible gender-dependent association of vascular endothelial growth factor (VEGF) gene and ALS (2006) (33)
Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease (2003) (33)
Cerebrospinal fluid findings in CADASIL (1999) (33)
Genetics of parkinson's disease (1998) (33)
Familial dopa-responsive cervical dystonia (2006) (32)
Haplotype analysis at the DYT1 Locus in ashkenazi jewish patients with occupational hand dystonia (1996) (32)
Extensive myelitis associated with Mycoplasma pneumoniae infection: magnetic resonance imaging and clinical long-term follow-up (2001) (31)
Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease. (2011) (31)
PARK11 is not linked with Parkinson's disease in European families (2005) (31)
Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease (2011) (30)
The α-synuclein gene in multiple system atrophy (2006) (30)
The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PDGBA (2021) (30)
The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease. (1998) (30)
Identification of a key recombinant narrows the CADASIL gene region to 8 cM and argues against allelism of CADASIL and familial hemiplegic migraine. (1996) (29)
Psychosocial problems of Parkinson patients: approaches to assessment and treatment. (1990) (29)
No association of GBA mutations and multiple system atrophy (2013) (29)
Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles (2020) (29)
Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2 (2018) (28)
Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease (2020) (28)
Partnership and depression in Parkinson's disease. (1992) (28)
New aspects of genetic contributions to Parkinson’s disease (2007) (28)
An omics-based strategy using coenzyme Q10 in patients with Parkinson’s disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial (2019) (27)
Linkage studies in alcohol‐responsive myoclonic dystonia (1996) (27)
An Interleukin-6 Promoter Variant Is Not Associated with an Increased Risk for Alzheimer’s Disease (2004) (27)
CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories (2020) (27)
No Dopamine Cell Loss or Changes in Cytoskeleton Function in Transgenic Mice Expressing Physiological Levels of Wild Type or G2019S Mutant LRRK2 and in Human Fibroblasts (2015) (27)
Involuntary eyelid closure after STN-DBS: evidence for different pathophysiological entities (2010) (26)
Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies (2021) (26)
Association of Clusterin Gene Polymorphisms with Late-Onset Alzheimer’s Disease (2011) (26)
Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia (2012) (26)
Lack of association between the interleukin-1 alpha (−889) polymorphism and early-onset Parkinson's disease (2004) (25)
Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease. (2010) (25)
Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM‐SPECT in a Wilson's disease patient with generalized dystonia (1992) (25)
Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review (2015) (25)
The CACNA1B R1389H variant is not associated with myoclonus-dystonia in a large European multicentric cohort (2015) (25)
Nonviral glial cell-derived neurotrophic factor gene transfer enhances survival of cultured dopaminergic neurons and improves their function after transplantation in a rat model of Parkinson's disease. (2000) (24)
Glial cell line‐derived neurotrophic factor up‐regulates GTP‐cyclohydrolase I activity and tetrahydrobiopterin levels in primary dopaminergic neurones (2002) (24)
New family with paroxysmal exercise‐induced dystonia and epilepsy (2007) (24)
HPCA confirmed as a genetic cause of DYT2‐like dystonia phenotype (2018) (24)
Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors (2016) (24)
A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance (2014) (24)
Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism (2002) (24)
A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease (2007) (24)
Large-scale assessment of polyglutamine repeat expansions in Parkinson disease (2015) (23)
GBA-associated PD (2012) (23)
Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. (2010) (23)
Search for the PARK3 founder haplotype in a large cohort of patients with Parkinson's disease from Northern Germany (1999) (23)
Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia (2016) (23)
Parkin Modulates Gene Expression in Control and Ceramide-Treated PC12 Cells (2006) (23)
Alpha2 macroglobulin and the risk of Alzheimer's disease. (2000) (23)
Nutrition and the risk for Parkinson’s disease: review of the literature (2008) (22)
Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease (2021) (22)
The role of α-synuclein gene multiplications in early-onset Parkinson’s disease and dementia with Lewy bodies (2005) (22)
A polymorphism in the intronic region of the IL-1α gene and the risk for Parkinson’s disease (2001) (22)
A novel homozygous DJ1 mutation causes parkinsonism and ALS in a Turkish family. (2016) (22)
Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease (2021) (22)
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
Cognitive impairment in Glucocerebrosidase (GBA)‐associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles (2017) (21)
Expression profiling in peripheral blood reveals signature for penetrance in DYT1 dystonia (2010) (21)
LINGO1 is not associated with Parkinson's disease in German patients (2010) (21)
LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death. (2017) (21)
EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts (2014) (21)
EFNS task force on molecular diagnosis of neurologic disorders Guidelines for the molecular diagnosis of inherited neurologic diseases First of two parts (2001) (21)
Broad clinical phenotype in Parkinsonism associated with a base pair deletion in RAB39B and additional POLG variant. (2016) (21)
Identification of sixteen novel candidate genes for late onset Parkinson’s disease (2021) (21)
EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias (2010) (21)
Cooperative Genome-Wide Analysis Shows Increased Homozygosity in Early Onset Parkinson's Disease (2012) (21)
Insulin sensitivity predicts cognitive decline in individuals with prediabetes (2020) (21)
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinsons disease (vol 22, pg 1696, 2013) (2013) (21)
Corrigendum to Using genome-wide complex trait analysis to quantify 'missing heritability' in parkinson's disease [Human Molecular Genetics, 21: 22 (2012) 4996-5009] doi: 10.1093/hmg/dds335] (2013) (21)
Effect of carbamazepine on stimulus-evoked Ca2+ fluxes in rat hippocampal slices and its interaction with A1-adenosine receptors (1988) (20)
Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease (2016) (20)
The human sideroflexin 5 (SFXN5) gene: sequence, expression analysis and exclusion as a candidate for PARK3. (2002) (20)
The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. (2001) (20)
Molecular genetics of Parkinson's disease. (2001) (20)
A novel SOD1 mutation in an Austrian family with amyotrophic lateral sclerosis (1997) (20)
A case of amyotrophic lateral sclerosis with a very slow progression over 44 years (2001) (20)
Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease (2018) (19)
The Parkinson’s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4 (2019) (19)
The Birth of the Modern Era of Parkinson’s Disease Genetics (2017) (19)
Markedly different course of Friedreich’s ataxia in sib pairs with similar GAA repeat expansions in the frataxin gene (1999) (19)
Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson’s disease (2012) (19)
Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse (2007) (19)
Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. (2015) (19)
Clinical variability in ataxia–telangiectasia (2015) (19)
A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson’s disease (2020) (18)
Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease (2019) (18)
Is the MC1R variant p.R160W associated with Parkinson's? (2016) (18)
Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha‐synuclein profile (2019) (18)
CHCHD2 and Parkinson's disease (2015) (18)
Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine‐rich repeat kinase 2 (2014) (18)
UCHL‐1 gene in multiple system atrophy: A haplotype tagging approach (2005) (18)
The European Reference Network for Rare Neurological Diseases (2021) (17)
Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders (2014) (17)
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial (2021) (17)
From genome-wide association studies to next-generation sequencing: lessons from the past and planning for the future. (2014) (17)
Establishing the role of rare coding variants in known Parkinson's disease risk loci (2017) (17)
Transcriptional regulation of the α-synuclein gene in human brain tissue (2015) (17)
DYT7 gene locus for cervical dystonia on chromosome 18p is questionable (2012) (17)
PLA2G6 Mutations Related to Distinct Phenotypes: A New Case with Early-onset Parkinsonism (2016) (17)
SIDE-EFFECTS OF SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE (1989) (17)
Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms (2018) (16)
Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation (2019) (16)
A unique case of coincidence of early onset Parkinson's disease and multiple sclerosis (2007) (16)
The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. (2005) (15)
Rapid detection of a pentanucleotide deletion polymorphism in the human alpha2-macroglobulin gene. (1999) (15)
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease (2021) (15)
Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. (2018) (15)
Human Dopaminergic Neurons Lacking PINK1 Exhibit Disrupted Dopamine Metabolism Related to Vitamin B6 Co-Factors (2020) (15)
The Autosomal Dominant Dystonias (1992) (15)
Familial carpal tunnel syndrome: further evidence for a genetic contribution (2005) (15)
Cervical dystonia in monozygotic twins: Case report and review of the literature (2001) (15)
The variable phenotype of FXTAS (2005) (14)
Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease (2005) (14)
Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis (2006) (14)
Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families (2007) (14)
Genome-Wide Association Analysis of the Sense of Smell in U.S. Older Adults: Identification of Novel Risk Loci in African-Americans and European-Americans (2017) (14)
Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors (2007) (14)
α2-Macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease (2006) (14)
Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information (2020) (14)
Genetic Architecture of Parkinson's Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research (2020) (14)
Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease (2018) (13)
A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease (2009) (13)
Effective long-term subthalamic stimulation in PARK8 positive Parkinson’s disease (2010) (13)
No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases (2009) (13)
LRP10 in α-synucleinopathies (2018) (13)
Integrative Pathway-Based Approach for Genome-Wide Association Studies: Identification of New Pathways for Rheumatoid Arthritis and Type 1 Diabetes (2013) (12)
IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome. (1993) (12)
No evidence for THAP1/DYT6 variants as disease modifiers in DYT1 dystonia (2011) (12)
Botulinum toxin A in orthopaedic surgery (1991) (11)
EFNS task force on molecular diagnosis of neurologic disorders Guidelines for the molecular diagnosis of inherited neurologic diseases Second of two parts (2001) (11)
a-Synuclein and Parkinson's Disease (2010) (11)
Mutations in CIZ1 are not a major cause for dystonia in Germany (2015) (11)
PIAS2-mediated blockade of IFN-β signaling: a basis for sporadic Parkinson disease dementia (2021) (11)
Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany (2009) (11)
Liposome-mediated gene transfer to fetal human ventral mesencephalic explant cultures (2001) (11)
Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease (2018) (10)
Parkinson’s disease: evolution of cognitive impairment and CSF Aβ1–42 profiles in a prospective longitudinal study (2018) (10)
Unmet Needs in Dystonia: Genetics and Molecular Biology—How Many Dystonias? (2017) (10)
Alpha‐synuclein gene variants may predict neurostimulation outcome (2016) (10)
Data protection in biomaterial banks for Parkinson's disease research: The model of GEPARD (Gene bank Parkinson's Disease Germany) (2007) (10)
Rapid emergence of temporal and pulvinar lesions in MELAS mimicking Creutzfeldt-Jakob disease (2011) (10)
Comprehensive association analysis of the NOS2A gene with Parkinson disease (2006) (10)
Understanding the role of genetic variability in LRRK2 in Indian population (2018) (9)
Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy--clinical projects in the BMFT-research program Munich: "Parkinson's diseas (1995) (9)
Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells (2008) (9)
Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey. (2017) (9)
Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis (2006) (9)
Dementia in Parkinson ’ s disease Author : Doctor (2004) (9)
[Local injection treatment with botulinum toxin A in blepharospasm, Meige syndrome and hemifacial spasm. Observations in 106 patients]. (1990) (9)
Autosomal-dominantly inherited forms of Parkinson's disease. (2000) (9)
GBA‐associated parkinsonism and dementia: beyond α‐synucleinopathies? (2016) (9)
No association between NOD2 variants and Parkinson's disease (2012) (9)
Spasmodic torticollis - a multicentre study on behavioural aspects III: psychosocial changes and coping. (1996) (9)
Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study (2017) (9)
Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. (2006) (9)
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. (2021) (9)
In vivo markers of Parkinson’s disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody (2014) (8)
Reverse sensory geste in cervical dystonia (2009) (8)
Kick and rush (2008) (8)
Copper genes are not implicated in the pathogenesis of focal dystonia. (2002) (8)
Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer’s disease with FDG-PET (2019) (8)
Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells. (2009) (8)
Is Parkinson's disease an inherited condition? (1999) (8)
Advances in the genetics of movement disorders: implications for molecular diagnosis (1997) (8)
Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants (2014) (8)
Fruit flies, bile acids, and Parkinson disease (2015) (8)
Using genome-Wwide complex trait analysis to quantify 'missing heritability' in Parkinson's disease (2012) (8)
Genetic testing in neurological diseases (2012) (8)
The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease (2021) (8)
Hunting for genes and mutations (2008) (7)
Moving Beyond Syndromic Classifications in Neurodegenerative Disease: The Example of PLA2G6 (2017) (7)
Paroxysmal choreoathetosis – a disorder related to Huntington’s disease? (1997) (7)
SNPs in A&bgr; clearance proteins: Lower CSF A&bgr;1-42 levels and earlier onset of dementia in PD (2017) (7)
High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. (2005) (7)
Variation in PARK10 is not associated with risk and age at onset of Parkinson's disease in large clinical cohorts (2015) (7)
Idiopathic, myoclonic and Dopa-responsive dystonia. (1997) (7)
Dual-Task Performance in GBA Parkinson's Disease (2017) (7)
Folinic acid therapy fails to improve early Parkinson's disease: a two week placebo controlled clinical trial (1992) (7)
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]. (2001) (7)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture (2020) (7)
CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB (2021) (7)
Polygenic Risk Scores Contribute to Personalized Medicine of Parkinson’s Disease (2021) (7)
Special issue “Parkinson’s disease” (2018) (7)
Erratum: A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease [Human Molecular Genetics 22, 5, 2013, 1039-1049] doi:10.1093/hmg/dds492 (2014) (7)
Needs and Requirements of Modern Biobanks on the Example of Dystonia Syndromes (2017) (6)
MAPT p.V363I mutation (2019) (6)
Lipid-Mediated Glial Cell Line-Derived Neurotrophic Factor Gene Transfer to Cultured Porcine Ventral Mesencephalic Tissue (2002) (6)
Replication of a Novel Parkinson's Locus in a European Ancestry Population (2021) (6)
Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease (2020) (6)
Autosomal-dominant Parkinson's disease linked to 2p13 is not caused by mutations in transforming growth factor alpha (TGF alpha) (2001) (6)
Functional Characterization of Rare RAB12 Variants and Their Role in Musician’s and Other Dystonias (2017) (6)
Severe muscular fasciculations as an uncommon side‐effect due to microdefect of an extension wire in deep brain stimulation (2009) (6)
CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers (2022) (6)
Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson’s disease: assessment of changes in DAT binding with [123I]IPT SPECT (2004) (6)
Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany (2010) (6)
[Hereditary CADASIL cerebral arteriopathy. Report of a family]. (1995) (6)
Primary cilia and SHH signaling impairments in human and mouse models of Parkinson’s disease (2022) (6)
Bi-allelic variants in TSPOAP1, encoding the active zone protein RIMBP1, cause autosomal recessive dystonia (2020) (5)
Molecular genetic findings in LRRK2 American, Canadian and German families. (2006) (5)
No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease (2013) (5)
P4-369: Lithium trial in Alzheimer's disease: A randomized, single-blinded, placebo-controlled, parallel group multicentre 10-week study (2008) (5)
Genetics of Parkinson's disease (2004) (5)
Parkinson's disease: Is it all in the genes? (2013) (5)
THE D2 RECEPTOR NCOI ALLELE : ABSENCE OF ALLELIC ASSOCIATION WITH MIGRAINEWITH AURA. AUTHOR'S REPLY (1998) (5)
Clinical course of subacute HIV encephalitis (1988) (5)
Mitochondrial and autophagy-lysosomal pathway polygenic risk scores predict Parkinson's disease (2022) (4)
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study (2022) (4)
SNPs in Aβ clearance proteins (2017) (4)
NIPA 1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis (2012) (4)
Slowly progressive Parkinson syndrome due to thalamic butterfly astrocytoma (2011) (4)
Integrated molecular landscape of Parkinson’s disease (2017) (4)
The restless legs syndrome—A genetic view of the disease (2002) (4)
Parkin and Its Role in Parkinson’s Disease (2004) (4)
Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors (2022) (4)
Genome-wide association studies of LRRK2 modifiers of Parkinson's disease (2020) (4)
[Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors]. (2008) (4)
Peripheral markers in Parkinson's disease. An overview. (1996) (4)
Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease (2022) (4)
Parkinson Disease and Other Synucleinopathies (2015) (4)
Neurodegenerative Diseases: Genetics of parkinsonism (2005) (3)
Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing (2017) (3)
The CYP 2 D 6 B allele is not overrepresented in a population of German patients with idiopathic Parkinson ' s disease (2003) (3)
Parkinson's syndrome in a young patient with Klinefelter's syndrome —A case report (2008) (3)
[Neurogenetics--the challenge for neurology. 1. Neurogenetic diseases]. (1991) (3)
SNPs in A beta clearance proteins Lower CSF A beta(1-42) levels and earlier onset of dementia in PD (2017) (3)
Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage (2021) (3)
Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease (2009) (3)
Parkinson disease GWAS (2015) (3)
A rare cause of corticobasal degeneration (3)
[Genetic counseling and prenatal diagnosis in mitochondrial diseases]. (1999) (3)
Cholinergic Pathway SNPs and Postural Control in 477 Older Adults (2018) (3)
Epsilon-sarcoglycan is not involved in sporadic Gilles de la Tourette syndrome (2005) (3)
The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease (2020) (3)
Private variants in PRKN are associated with late-onset Parkinson's disease. (2020) (3)
Huntington's Disease and Sydenham's Chorea (2003) (3)
The Interaction between HLA‐DRB1 and Smoking in Parkinson's Disease Revisited (2022) (2)
Personalized Medicine Approaches in Parkinson's Disease: The Genetic Perspective. (2016) (2)
LRRK2: Understanding the role of common and rare variants in Parkinson's disease (2012) (2)
Criteria for Prodromal Parkinson ’ s Disease (2015) (2)
THROMBOPROPHYLAXIS WITH DALTERPARINE FOR TRANSURETHRAL SURGERY, A DOUBLE-BLIND PLACEBO-CONTROLLED, RANDOMISED STUDY (2009) (2)
Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease (2009) (2)
Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease (2022) (2)
Self estimated quality of life in monogenetic Parkinson's disease (2011) (2)
[Personalized diagnostics and treatment in neurology : Prospect and challenge]. (2019) (2)
Primary central nervous system vasculitis in a child mimicking parasitosis (2008) (2)
Clonal Hematopoiesis as a pitfall in germline variant interpretation in the context of Mendelian disorders. (2022) (2)
Somatic gene therapy in animal models of Parkinson's disease. (1999) (2)
Dementia in Parkinson's disease (2004) (2)
Genetic Analysis of Leucin-Rich Repeat Kinase 2 (LRRK2 ) G2019S Mutation in a Sample of Egyptian Patients with Parkinson's Disease, a Pilot Study (2015) (2)
Meta analysis of whole-genome linkage scans with data uncertainty: an application to Parkinson's disease (2007) (2)
[Molecular diagnosis of hereditary neurologic diseases. Position paper]. (2000) (2)
Overview of the New European Federation of Neurological Societies’ Guidelines on Molecular Diagnosis of Neurological Disorders (2010) (2)
[Current pharmacologic therapy of idiopathic Parkinson's syndrome]. (1999) (1)
Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in Parkinson disease patients with a GBA mutation from Japan and the rest of the world: Results from part 1 of the MOVES-PD study (2020) (1)
Spectrum of mutations in the gene for epsilon-sarcoglycan (SGCE) in myoclonus-dystonia syndrome (MDS, DYT11) (2002) (1)
Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson's disease (2008) (1)
Genetics of Atypical Parkinsonism Implications for Nosology (2004) (1)
Mutations in the GCH1 Gene Are Associated with Parkinson Disease (S17.001) (2014) (1)
Generation of induced pluripotent stem cells derived from a 77-year-old healthy woman as control for age related diseases. (2016) (1)
[Genetic risk factors for neuropsychiatric disorders]. (2017) (1)
MAPT p.V363I mutation A rare cause of corticobasal degeneration (1)
[CADASIL: clinical aspects and diagnosis]. (1998) (1)
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement]. (2008) (1)
Evaluation of the Dementia Apraxia Test in Parkinson’s Disease Patients (2022) (1)
Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes. (1996) (1)
[Personalized treatment of Parkinson's disease]. (2019) (1)
Deletions at 22q11.2 in idiopathic Parkinson's disease: A combined analysis of GWAS data (2016) (1)
Improving statistical analysis in brain imaging: an alternative way to use principal component analysis (2018) (1)
Diagnosis and Treatment of Primary (Idiopathic) Dystonia (2010) (1)
Erratum: Complex relationship between Parkin mutations and Parkinson disease (American Journal of Medical Genetics-Neuropsychocetric (2002) 114-(584-591)) (2002) (1)
[Neurogenetics--the challenge for neurology. Part 1. Gene mapping and gene diagnostics]. (1991) (1)
Interferon-γ signaling synergizes with LRRK2 in human neurons and microglia (2020) (1)
Quantifying activities of daily living impairment in Parkinson’s disease using the Functional Activities Questionnaire (2021) (1)
Association between the vascular endothelial growth factor (VEGF) gene and amyotrophic lateral sclerosis (ALS): possible gender-dependent effect (2006) (1)
Familial dopa-responsive cervical dominant dystonia (2006) (1)
Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease [Neuroscience Letters 342 (2003) 132–134] (2003) (1)
LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism (2008) (1)
LifeTime and improving European healthcare through cell-based interceptive medicine (2020) (1)
Genetics of Atypical Parkinsonism (2005) (1)
Botulinum toxin A injections in phantom pain patients are not a useful treatment option – a case series (2007) (0)
Oral venglustat in Parkinson disease patients with a mutation: Study design of part 2 of the MOVES-PD trial and patient characteristics (2021) (0)
PARK6 is a major locus in early-onset parkinsonism (2001) (0)
Frontotemporal dementia Author : Doctor (2004) (0)
[Neurogenetics. Part 3. New developments in gene mapping and diagnosis]. (1993) (0)
Novel ATP1A3 mutation in a sporadic RDP patient with partial benefit from deep brain stimulation (2007) (0)
Molecular Diagnosis of Ataxias and Spastic Paraplegias (2011) (0)
MEMORY FUNCTION IS ASSOCIATED WITH TAU PATHOLOGY IN PARKINSON’S DISEASE (2019) (0)
IdentIFICatIon oF noVel BIoMarKer CandIdates In tHe CereBrosPInal FluId ProteoMe oF druG-naïVe ParKInson’s dIsease PatIents (2014) (0)
1815-P: Insulin Sensitivity Predicts Cognitive Decline in Prediabetes (2019) (0)
Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information (2020) (0)
Genotype–Phenotype correlations of SCARB2 associated clinical presentation: a case report and in-depth literature review (2022) (0)
Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System. (2017) (0)
P4-226 GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR IN LITHIUM-TREATED PATIENTS WITH EARLYALZHEIMER’S DISEASE (2019) (0)
ENS TEACHING REVIEW (0)
Supplemental Data: PLA2G6 Mutations Related to Distinct Phenotypes: A New Case with Early-onset Parkinsonism (2016) (0)
Reply to: “α‐Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism” (2021) (0)
Directed differentiation of neural epithelial cells into mDANs. (2013) (0)
Twenty-second Meeting of the European Neurological Society 9–12 June, 2012 Prague, Czech Republic (2012) (0)
578 THROMBOPROPHYLAXIS WITH DALTERPARINE FOR TRANSURETHRAL SURGERY, A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY (2009) (0)
Publisher Correction: Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes (2022) (0)
GLUT1 MUTATIONS IN PATIENTS WITH PAROXYSMAL EXERTION-INDUCED DYSKINESIA (2009) (0)
Genetic Reports Abstracts Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease (2011) (0)
Molecular Genetic Diagnosis of Neurological Diseases (2003) (0)
SWATH Mass Spectrometry-Based CSF Proteome Profile of GBA-Linked Parkinson’s Disease Patients (2022) (0)
Apomorphin in der Therapie und Differentialdiagnose von Parkinson Syndromen (1991) (0)
Molecular Diagnosis of Channelopathies, Epilepsies, Migraine, Stroke and Dementias (2011) (0)
The deleterious effects of High Mobility Group Box 1 in the MPTP model and Parkinson's disease can be attenuated by glycyrrhizin (2014) (0)
Response to letter by Dr Neil Murray (2011) (0)
VBM in epsilon-sarcoglycan mutation positive myoclonus-dystonia (2005) (0)
[Introduction to Gene Therapy]. (2023) (0)
Molecular Diagnosis of Neurogenetic Disorders: Motoneuron, Peripheral Nerve and Muscle Disorders (2011) (0)
Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication (2006) (0)
Publisher Correction: LifeTime and improving European healthcare through cell-based interceptive medicine (2021) (0)
Impact of APOE genotype on cognition in idiopathic and genetic forms of Parkinson's disease. (2022) (0)
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients With Parkinson's Disease and a GBA Mutation: Results From Part 1 of the Randomised, Double-Blinded, Placebo-Controlled MOVES-PD Trial (2021) (0)
Rapid emergence of temporal and pulvinar lesions in MELAS mimicking Creutzfeld-Jakob disease (copy of NEUROLOGY/2011/389635) (2012) (0)
Faculty Opinions recommendation of Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. (2008) (0)
Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions (2020) (0)
Idiopathic Torsion Dystonia (2004) (0)
New Insights into Disease and Pathogen Research Vol. 1 (2019) (0)
Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease (2022) (0)
II.P16 Osteopontin is elevated in Parkinson's Disease (PD) and PD with dementia (2006) (0)
Age at onset as stratifier in idiopathic Parkinson’s disease – effect of ageing and polygenic risk score on clinical phenotypes (2022) (0)
Inflammatory profile in LRRK2-associated prodromal and clinical PD (2016) (0)
In reply. (2013) (0)
P2-082 A randomised, single-blind, placebo-controlled, multicentre study to investigate the pharmacodynamic effects of lithium on GSK-3 activity in patients with mild Alzheimer’s disease (2006) (0)
University of Dundee Interrogating Parkinson ' s disease LRRK 2 kinase pathway activity by assessing Rab 10 phosphorylation in human neutrophils (2017) (0)
[Modern medical therapy for idiopathic Parkinson syndrome]. (2000) (0)
Contents Vol. 37, 2011 (2011) (0)
Early diagnosis of Parkinson's disease syndromes - Not quite trivial, but prognostically and therapeutically relevant (2009) (0)
P14 Co-activation of antagonistic muscles in Parkinson’s disease: A pathophysiological correlate of PD motor impairment? (2011) (0)
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2020) (0)
Glial cell line-derived neurotrophic factor in lithium-treated patients with early Alzheimer's disease (2011) (0)
The Parkinson’s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4 (2019) (0)
A missense mutation in the KCTD17 gene causes autosomal dominant myoclonus-dystonia (2015) (0)
A genome-wide genetic pleiotropy approach identified shared loci between multiple system atrophy and inflammatory bowel disease (2019) (0)
Assessment of SLC25A46 variants in Parkinson's disease (2022) (0)
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]. (2001) (0)
Disease-oriented Genome Networks Diseases of the Nervous System Network : Systematic Gene Identification and Functional Analyses in Common CNS Disorders Project : Identification of Genetic Risk Factors of Parkinsons Disease (2005) (0)
Silent Saliva Aspiration in Parkinson ’ s Disease (2011) (0)
Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability (2019) (0)
Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders (2014) (0)
Transcriptional effects of conditional parkin-overexpression in PC12-cells (2007) (0)
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in the Japanese and the Rest of the World Parkinson’s Disease Population With a GBA Mutation: Results from Part 1 of the MOVES-PD Study (809) (2020) (0)
Reply (2010) (0)
P3-280 Higher peripheral regulatory T cell activity in parkinson but not Alzheimer’s disease (2006) (0)
Faculty Opinions recommendation of Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. (2004) (0)
[Typical anticipation in type 7 spinocerebellar ataxia]. (2000) (0)
Genotype-Phenotype correlation in Parkin-Parkinson’s disease (P3-11.012) (2023) (0)
Special issue “Parkinson’s disease” (2018) (0)
Metabolic Fatty Liver Disease (2009) (0)
Contents Vol. 23, 2007 (2007) (0)
[Introduction to neurogenetics]. (2013) (0)
Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset (2019) (0)
Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism (2023) (0)
Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies (2021) (0)
The PDXK rs2010795 Variant Is Not Associated with Parkinson Disease in Italy [reply] (2010) (0)
LRRK2 ASSOCIATED PARKINSON'S DISEASE: CLINICAL FACTORS BASED ON WORLDWIDE EXPERIENCE (2009) (0)
Parkinson's Disease: Genetics, Mechanisms and Therapeutics (2014) (0)
Principles of molecular genetics/Dystonia (1992) (0)
A GLUT1 mutation in patients with spastic paraplegia and paroxysmal dyskinesia (2009) (0)
idiopathic Parkinson ' s disease . a population of German patients with The CYP 2 D 6 B allele is not overrepresented in (2003) (0)
Genetic testing for Parkinson's disease in clinical practice. (2023) (0)
Words of wisdom. Re: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. (2007) (0)
Genome-Wide Association Analysis of the Sense of Smell in U.S. Older Adults: Identification of Novel Risk Loci in African-Americans and European-Americans (2016) (0)
LifelineS Okun graduated from the neurology (2012) (0)
Molecular Diagnosis of Neurogenetic Disorders: General Issues, Huntington's Disease, Parkinson's Disease and Dystonias (2011) (0)
P126 LINGO1 is not associated with Parkinson’s disease in German patients (2011) (0)
High COMT activity is associated with earlier age at onset in PD (2013) (0)
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease (2021) (0)
Subject Index Vol. 23, 2007 (2007) (0)
Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding (2022) (0)
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers (2023) (0)
Molecular Diagnosis of Mitochondrial Disorders (2011) (0)
Genetic Basis of Monogenic Forms of Parkinson Disease (2010) (0)
Supplementary Material for: Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia (2016) (0)
Machine learning-based personalized composite score dissects risk and protective factors for cognitive and motor function in elderly (2022) (0)
Genetic Basis of Monogenic Forms of (2010) (0)
Case Report: Deep brain stimulation improves tremor in FGF-14 associated spinocerebellar ataxia (2022) (0)
PINK1 Regulates Dopamine and Lipids at Mitochondria to Maintain Synapses and Neuronal Function (2019) (0)
The role of inflammation in sporadic and familial Parkinson’s disease (2013) (0)
Oral session 4 — Cerebrovascular disorders (2) (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas C. Gasser?

Thomas C. Gasser is affiliated with the following schools:

University of Tübingen

Thomas C. Gasser's Academic­Influence.com Rankings

Thomas C. Gasser's Degrees

Why Is Thomas C. Gasser Influential?

Thomas C. Gasser's Published Works

Published Works

What Schools Are Affiliated With Thomas C. Gasser?

Thomas C. Gasser's AcademicInfluence.com Rankings